Bristol-Myers Squibb Company

NYSE: BMY
$49.41
+$0.39 (+0.8%)
Closing Price on September 20, 2024

BMY Articles

October 11, 2016: Here are four stocks trading with relatively heavy volume among 69 equities making new 52-week lows in Tuesday’s session. On the NYSE, decliners led advancers by about 7 to 1 and...
October 7, 2016: Here are four stocks trading with relatively heavy volume among 26 equities making new 52-week lows in Monday’s session. On the NYSE, advancers led decliners by about 2.5 to 1 and...
On Monday morning, Merck, Mylan and Bristol-Myers Squibb made substantial runs, either up or down.
October 3, 2016: Here are four stocks trading with relatively heavy volume among 29 equities making new 52-week lows in Monday’s session. Wells Fargo & Co. (NYSE: WFC) lost about 1.6% Monday to...
September 28, 2016: Here are four stocks trading with relatively heavy volume among 33 equities making new 52-week lows in Wednesday’s session. NYSE advancers led decliners by nearly 7 to 3 and...
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
September 12, 2016: Here are four stocks trading with relatively heavy volume among 56 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by more than 2 to 1 and...
September 2, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by nearly 4 to 1 and Nasdaq...
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
The top analyst upgrades, downgrades and initiations seen on Monday morning include BlackRock, Bristol-Myers, Level 3, NVIDIA, Monsanto and Twenty-First Century Fox.
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.